Allogene Therapeutics Inc. [ALLO] Is Currently 10.22 below its 200 Period Moving Avg: What Does This Mean?


Allogene Therapeutics Inc. [NASDAQ: ALLO] closed the trading session at $10.46 on 06/08/22. The day’s price range saw the stock hit a low of $9.36, while the highest price level was $10.59. The company report on June 8, 2022 that Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL).

Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Effective in Producing Durable Responses.

The stocks have a year to date performance of -29.89 percent and weekly performance of 35.84 percent. The stock has been moved at -44.21 percent over the last six months. The stock has performed 42.70 percent around the most recent 30 days and changed 18.59 percent over the most recent 3-months.

If compared to the average trading volume of 1.83M shares, ALLO reached to a volume of 3589006 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Allogene Therapeutics Inc. [ALLO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $26.06 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Robert W. Baird have made an estimate for Allogene Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 03, 2022. While these analysts kept the previous recommendation, B. Riley Securities dropped their target price from $30 to $21. The new note on the price target was released on February 28, 2022, representing the official price target for Allogene Therapeutics Inc. stock. On October 08, 2021, analysts decreased their price target for ALLO shares from 44 to 18.

The Average True Range (ATR) for Allogene Therapeutics Inc. is set at 0.74, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 7103.91. The Price to Book ratio for the last quarter was 1.73, with the Price to Cash per share for the same quarter was set at 3.31.

ALLO stock trade performance evaluation

Allogene Therapeutics Inc. [ALLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 35.84. With this latest performance, ALLO shares gained by 42.70% in over the last four-week period, additionally sinking by -44.21% over the last 6 months – not to mention a drop of -57.94% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 71.45, with the RSI for the last a single of trading hit 79.90, and the three-weeks RSI is set at 64.91 for Allogene Therapeutics Inc. [ALLO]. The present Moving Average for the last 50 days of trading for this stock 8.33, while it was recorded at 8.84 for the last single week of trading, and 14.20 for the last 200 days.

Allogene Therapeutics Inc. [ALLO]: An insightful look at the core fundamentals

Allogene Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.70 and a Current Ratio set at 12.70.

Earnings per share (EPS) analysis for Allogene Therapeutics Inc. [ALLO] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc. go to 1.00%.

Allogene Therapeutics Inc. [ALLO]: Insider Ownership positions

There are presently around $1,046 million, or 64.70% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: TPG GP A, LLC with ownership of 18,716,306, which is approximately 0% of the company’s market cap and around 3.10% of the total institutional ownership; TPG GROUP HOLDINGS (SBS) ADVISORS, INC., holding 18,716,306 shares of the stock with an approximate value of $177.62 million in ALLO stocks shares; and STATE STREET CORP, currently with $74.76 million in ALLO stock with ownership of nearly 78.508% of the company’s market capitalization.

Positions in Allogene Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 106 institutional holders increased their position in Allogene Therapeutics Inc. [NASDAQ:ALLO] by around 16,319,048 shares. Additionally, 77 investors decreased positions by around 10,346,325 shares, while 32 investors held positions by with 83,597,347 shares. The mentioned changes placed institutional holdings at 110,262,720 shares, according to the latest SEC report filing. ALLO stock had 33 new institutional investments in for a total of 2,799,746 shares, while 33 institutional investors sold positions of 6,900,042 shares during the same period.